ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients

Interim results of a small phase II study found a relatively good response rate with dabrafenib in BRAF V600E mutation-positive stage IV non-small-cell lung cancer (NSCLC) patients. The results were presented at ASCO.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news